Life Sciences Research Night
Life Sciences Research Night (LSRN) is the signature annual event of UBC URO. LSRN brings together world-class PIs, industry professionals, UBC faculty, and experienced graduate/undergraduate researchers to help undergraduate students network and discover research opportunities. In partnership with many organizations LSRN offers 15+ cutting-edge workshops —all in one memorable evening!
RSVP for LSRN 2024
RSVP now for Life Sciences Research Night on November 25th, 2024!
Choose to only attend the event, or to also register to present your own research in the poster session for the UBC and life sciences community.
Choose to only attend the event, or to also register to present your own research in the poster session for the UBC and life sciences community.
Event Schedule
This timeline highlights the key stages of events for Life Sciences Research Night, with “A” and “B” representing Part 1 and Part 2 of the workshops, respectively.
Keynote Address (5:30 – 6:00 PM)
External Partner Intro (6:00 – 6:10 PM)
External Partner Intro (6:00 – 6:10 PM)
- Research Opportunities at The BC Children’s Hospital (A)
- Canadian Journal of Undergraduate Research Panel
- General Graduate Studies Information
- How to Approach Faculty for Research Opportunities
- Research Opportunities at ICORD
- Research Opportunities at BC Children’s Hospital (B)
- Summer Research Opportunities: Centre for Blood Research (A)
- UBC Science Co-op
- Honours Thesis and Directed Studies
- Elevate Your Research Poster
- LinkedIn Essentials for Life Sciences Students: Networking You Way to Research Opportunities
- MD vs PhD vs MD/PhD
- How to Fund Your Undergraduate Research: SSRP & NSERC USRA Awards
- Summer Research Opportunities: Centre for Blood Research (B)
- UBC Student Design Teams
- Research Abroad: Go Global
- Acuitas Therapeutics
- NanoVation Therapeutics
LSRN Industry Sponsors 2024
We are pleased to announce our industry sponsors for LSRN 2024: Acuitas Therapeutics and NanoVation Therapeutics!
Acuitas Therapeutics
Vancouver-based Acuitas Therapeutics (www.acuitastx.com) partners with pharmaceutical and biotechnology companies, NGOs, and academic institutes to advance nucleic acid therapeutics into clinical development and commercialization.
Acuitas’ lipid nanoparticle (LNP) technology is clinically validated, enabling Alnylam Pharmaceuticals’ ONPATTRO® for treating transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, protecting billions in over 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is focused on further innovations to its LNP carriers for developing novel gene therapies, like epigenetic medicines to modulate gene expression without genetic editing for diseases, including cancer.
Acuitas collaborates on developing improved vaccines, like multi-valent vaccines to prevent infectious diseases (malaria, HIV/AIDS, and tuberculosis) and therapeutic vaccines against cancer, including personalized cancer vaccines.
Acuitas’ lipid nanoparticle (LNP) technology is clinically validated, enabling Alnylam Pharmaceuticals’ ONPATTRO® for treating transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, protecting billions in over 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is focused on further innovations to its LNP carriers for developing novel gene therapies, like epigenetic medicines to modulate gene expression without genetic editing for diseases, including cancer.
Acuitas collaborates on developing improved vaccines, like multi-valent vaccines to prevent infectious diseases (malaria, HIV/AIDS, and tuberculosis) and therapeutic vaccines against cancer, including personalized cancer vaccines.
NanoVation Therapeutics
NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. Our LNP technologies aim to overcome the limitations of existing nucleic acid delivery approaches, including the ability to target tissues outside the liver (extrahepatic delivery).
Their lead technology, the proprietary long-circulating LNP (lcLNP™) platform, enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies.
NanoVation partners with leading pharmaceutical and biotech companies to develop genetic medicines for previously untreatable diseases.
NTx is delivering tomorrow’s genetic medicines, today. For more information, please visit nanovationtx.com.
Their lead technology, the proprietary long-circulating LNP (lcLNP™) platform, enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies.
NanoVation partners with leading pharmaceutical and biotech companies to develop genetic medicines for previously untreatable diseases.
NTx is delivering tomorrow’s genetic medicines, today. For more information, please visit nanovationtx.com.
